 Michael Harris-Love
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle Strength | 13 | 2024 | 270 | 2.810 |
Why?
| | Myositis, Inclusion Body | 5 | 2015 | 11 | 1.530 |
Why?
| | Myositis | 8 | 2015 | 43 | 1.500 |
Why?
| | Ultrasonography | 4 | 2024 | 632 | 1.420 |
Why?
| | Muscle, Skeletal | 11 | 2024 | 1417 | 1.030 |
Why?
| | Heel | 2 | 2014 | 9 | 0.900 |
Why?
| | Quadriceps Muscle | 3 | 2024 | 102 | 0.830 |
Why?
| | Dermatomyositis | 6 | 2022 | 23 | 0.810 |
Why?
| | Gait | 5 | 2015 | 250 | 0.780 |
Why?
| | Lower Extremity | 3 | 2024 | 332 | 0.770 |
Why?
| | Multiple Sclerosis | 2 | 2024 | 363 | 0.770 |
Why?
| | Polymyositis | 5 | 2014 | 15 | 0.710 |
Why?
| | Exercise Therapy | 4 | 2013 | 351 | 0.710 |
Why?
| | Sarcoma, Kaposi | 2 | 2009 | 68 | 0.530 |
Why?
| | Physical Therapists | 1 | 2015 | 39 | 0.460 |
Why?
| | Isometric Contraction | 2 | 2013 | 154 | 0.450 |
Why?
| | Range of Motion, Articular | 2 | 2019 | 348 | 0.440 |
Why?
| | Ankle | 1 | 2013 | 70 | 0.430 |
Why?
| | Skin Neoplasms | 2 | 2009 | 755 | 0.330 |
Why?
| | Muscle Neoplasms | 1 | 2009 | 8 | 0.330 |
Why?
| | Knee Joint | 2 | 2009 | 321 | 0.330 |
Why?
| | Arthralgia | 1 | 2009 | 46 | 0.320 |
Why?
| | Middle Aged | 16 | 2024 | 26552 | 0.300 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2024 | 486 | 0.290 |
Why?
| | Friedreich Ataxia | 2 | 2009 | 64 | 0.290 |
Why?
| | Physicians | 1 | 2015 | 765 | 0.280 |
Why?
| | Severity of Illness Index | 6 | 2014 | 2530 | 0.260 |
Why?
| | Male | 22 | 2024 | 55112 | 0.240 |
Why?
| | Humans | 33 | 2024 | 113531 | 0.230 |
Why?
| | Motor Activity | 2 | 2009 | 623 | 0.220 |
Why?
| | Adult | 17 | 2024 | 30245 | 0.220 |
Why?
| | Foot Diseases | 1 | 2004 | 32 | 0.220 |
Why?
| | Muscle Weakness | 4 | 2013 | 81 | 0.220 |
Why?
| | Aged | 10 | 2024 | 18944 | 0.220 |
Why?
| | Exercise Tolerance | 2 | 2009 | 212 | 0.220 |
Why?
| | Weight-Bearing | 1 | 2004 | 161 | 0.210 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 81 | 0.210 |
Why?
| | HIV Infections | 2 | 2009 | 2440 | 0.210 |
Why?
| | Female | 20 | 2024 | 59115 | 0.210 |
Why?
| | Predictive Value of Tests | 4 | 2014 | 1783 | 0.200 |
Why?
| | Leg | 1 | 2004 | 218 | 0.200 |
Why?
| | Resistance Training | 1 | 2024 | 113 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 4400 | 0.200 |
Why?
| | Activities of Daily Living | 2 | 2009 | 348 | 0.200 |
Why?
| | Physical Therapy Modalities | 1 | 2004 | 265 | 0.180 |
Why?
| | Bulbo-Spinal Atrophy, X-Linked | 2 | 2011 | 3 | 0.180 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 633 | 0.170 |
Why?
| | Dance Therapy | 1 | 2019 | 3 | 0.160 |
Why?
| | Video Games | 1 | 2019 | 21 | 0.160 |
Why?
| | Muscular Diseases | 2 | 2015 | 101 | 0.160 |
Why?
| | Hand Strength | 1 | 2018 | 95 | 0.150 |
Why?
| | Infliximab | 1 | 2017 | 93 | 0.140 |
Why?
| | Dermatologic Agents | 1 | 2017 | 57 | 0.140 |
Why?
| | Kidney Failure, Chronic | 1 | 2022 | 490 | 0.140 |
Why?
| | Exercise | 3 | 2024 | 1617 | 0.130 |
Why?
| | Hypertension | 1 | 2024 | 1051 | 0.130 |
Why?
| | Reproducibility of Results | 5 | 2015 | 2752 | 0.120 |
Why?
| | International Cooperation | 1 | 2005 | 168 | 0.120 |
Why?
| | Accidental Falls | 2 | 2014 | 150 | 0.120 |
Why?
| | Aging | 1 | 2024 | 1601 | 0.120 |
Why?
| | Quality of Life | 2 | 2009 | 2335 | 0.110 |
Why?
| | Veterans | 1 | 2024 | 1248 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2004 | 185 | 0.100 |
Why?
| | Biomechanical Phenomena | 1 | 2015 | 664 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2014 | 211 | 0.100 |
Why?
| | Age Factors | 1 | 2018 | 2875 | 0.100 |
Why?
| | Disease Management | 1 | 2005 | 554 | 0.090 |
Why?
| | Azasteroids | 1 | 2011 | 4 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 922 | 0.090 |
Why?
| | Antirheumatic Agents | 1 | 2013 | 253 | 0.090 |
Why?
| | Patellofemoral Pain Syndrome | 1 | 2009 | 6 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1682 | 0.080 |
Why?
| | Ubiquinone | 1 | 2009 | 21 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 30 | 0.080 |
Why?
| | Analysis of Variance | 2 | 2008 | 1208 | 0.080 |
Why?
| | CD4 Lymphocyte Count | 1 | 2009 | 253 | 0.080 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2008 | 107 | 0.080 |
Why?
| | Child | 9 | 2022 | 18340 | 0.080 |
Why?
| | Muscle Stretching Exercises | 1 | 2008 | 17 | 0.080 |
Why?
| | Treatment Outcome | 8 | 2017 | 9006 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2005 | 1378 | 0.070 |
Why?
| | Viral Load | 1 | 2009 | 403 | 0.070 |
Why?
| | Radiography | 1 | 2009 | 803 | 0.070 |
Why?
| | Osteoarthritis, Knee | 1 | 2009 | 212 | 0.070 |
Why?
| | Linear Models | 1 | 2008 | 767 | 0.070 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2007 | 122 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2017 | 1643 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3013 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1328 | 0.060 |
Why?
| | Walkers | 1 | 2004 | 2 | 0.060 |
Why?
| | Lymphedema | 1 | 2004 | 20 | 0.060 |
Why?
| | Sickness Impact Profile | 1 | 2003 | 50 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2024 | 255 | 0.050 |
Why?
| | Task Performance and Analysis | 1 | 2004 | 160 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1236 | 0.050 |
Why?
| | Muscle Fatigue | 1 | 2003 | 89 | 0.050 |
Why?
| | Rituximab | 2 | 2014 | 146 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 407 | 0.050 |
Why?
| | Physical Fitness | 1 | 2003 | 178 | 0.050 |
Why?
| | Adolescent | 6 | 2013 | 17724 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2003 | 271 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2011 | 4384 | 0.050 |
Why?
| | Risk Factors | 1 | 2014 | 8606 | 0.050 |
Why?
| | Child, Preschool | 3 | 2009 | 9093 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 292 | 0.040 |
Why?
| | Cicatrix | 1 | 2009 | 50 | 0.040 |
Why?
| | Muscular Atrophy | 1 | 2009 | 74 | 0.040 |
Why?
| | Disease Progression | 2 | 2011 | 2364 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1205 | 0.040 |
Why?
| | Biomarkers | 1 | 2008 | 3389 | 0.040 |
Why?
| | Pilot Projects | 2 | 2017 | 1356 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2009 | 12504 | 0.040 |
Why?
| | Independent Living | 1 | 2019 | 84 | 0.040 |
Why?
| | Calcinosis | 1 | 2009 | 239 | 0.030 |
Why?
| | Prednisone | 1 | 2017 | 229 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 432 | 0.030 |
Why?
| | Prognosis | 1 | 2003 | 3318 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 712 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 944 | 0.030 |
Why?
| | Risk Assessment | 1 | 2003 | 2953 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6296 | 0.030 |
Why?
| | Inflammation | 1 | 2024 | 2444 | 0.030 |
Why?
| | Incidence | 1 | 2009 | 2310 | 0.030 |
Why?
| | Consensus | 1 | 2005 | 533 | 0.030 |
Why?
| | Muscle Contraction | 2 | 2008 | 386 | 0.030 |
Why?
| | Placebos | 1 | 2013 | 198 | 0.030 |
Why?
| | Observer Variation | 2 | 2006 | 298 | 0.030 |
Why?
| | Walking | 2 | 2009 | 421 | 0.020 |
Why?
| | Obesity | 1 | 2024 | 2501 | 0.020 |
Why?
| | Dutasteride | 1 | 2011 | 4 | 0.020 |
Why?
| | Pain Measurement | 1 | 2013 | 440 | 0.020 |
Why?
| | Electrodiagnosis | 1 | 2009 | 15 | 0.020 |
Why?
| | Gait Apraxia | 1 | 2009 | 1 | 0.020 |
Why?
| | Erectile Dysfunction | 1 | 2009 | 38 | 0.020 |
Why?
| | Neural Conduction | 1 | 2009 | 78 | 0.020 |
Why?
| | Alemtuzumab | 1 | 2009 | 12 | 0.020 |
Why?
| | Peripheral Nerves | 1 | 2009 | 64 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2009 | 131 | 0.020 |
Why?
| | Lymphocyte Depletion | 1 | 2009 | 115 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2013 | 520 | 0.020 |
Why?
| | Proprioception | 1 | 2008 | 19 | 0.020 |
Why?
| | Androgens | 1 | 2009 | 166 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 444 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 323 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 4593 | 0.020 |
Why?
| | Action Potentials | 1 | 2009 | 402 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 195 | 0.020 |
Why?
| | Autoantibodies | 1 | 2014 | 1349 | 0.020 |
Why?
| | Testosterone | 1 | 2009 | 341 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2009 | 469 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 368 | 0.020 |
Why?
| | Antioxidants | 1 | 2009 | 527 | 0.020 |
Why?
| | Fractures, Bone | 1 | 2011 | 366 | 0.020 |
Why?
| | Biopsy | 1 | 2009 | 1024 | 0.020 |
Why?
| | Recovery of Function | 1 | 2009 | 567 | 0.020 |
Why?
| | Physical Therapy Specialty | 1 | 2006 | 34 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 384 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 654 | 0.010 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2009 | 686 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 960 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1822 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2009 | 2507 | 0.010 |
Why?
| | Physical Examination | 1 | 2003 | 222 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2293 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6032 | 0.010 |
Why?
| | Exercise Test | 1 | 2000 | 546 | 0.010 |
Why?
|
|
Harris-Love's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|